Breast cancer risk prediction with a modified BOADICEA model in Danish women
- PMID: 41225192
- PMCID: PMC12820242
- DOI: 10.1038/s41416-025-03247-3
Breast cancer risk prediction with a modified BOADICEA model in Danish women
Abstract
Background: Breast cancer risk prediction approaches clinical practice. The BOADICEA risk model has been updated to consider common breast cancer risk variants, lifestyle/hormonal risk factors and mammographic density (MD).
Methods: 49,494 women from the Danish Blood Donor Study were followed for up to 10 years. Modified BOADICEA risks within 5 and 10 years were calculated based on a polygenic breast cancer risk score combined with lifestyle/hormonal risk factors. MD was only known for 4608 women. Calibration was assessed by comparing observed and predicted risks. AUC and Harrell's concordance index (C-index) were used to assess discriminative ability and sensitivities and specificities were obtained for high and low-risk groups.
Results: Within 5 and 10 years, 367 and 617 women had breast cancer. The 5-year model achieved an AUC of 0.80 (95% CI:0.78-0.81), sensitivity of 0.34 and specificity of 0.92 for all and an AUC of 0.61 (95% CI:0.58-0.65) for the 50-69-year-aged. For this age-group, the sensitivity was 0.46 in the 10-year model. 50% of women with the highest 5-year risk predictions, identified 94.8% of those with incident breast cancers.
Conclusion: The modified BOADICEA risk model provided valid risks among a large retrospective cohort of Danish women.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: ACA and LF are listed as creators of the BOADICEA model, which has been licensed from Cambridge Enterprise (University of Cambridge) for commercial purposes. SB has ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S, ALK abello A/S, Eli Lilly and Co and managing board memberships in Proscion A/S and Intomics A/S. All other authors declare no competing interests. Consent for publication: All authors consented to publication of this manuscript. Ethics approval and consent to participate: All DBDS participants gave informed consent. All methods were performed in accordance with the relevant guidelines and regulations. This study was approved by the National Committee on Health Research Ethics (M-20090237/1-10-72-95-13, NVK-1700407 and SJ-740) and the data protection in the Capital Region of Denmark (P-2019-99).
Figures
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49. - PubMed
-
- Larønningen S, Ferlay J, Beydogan H, Bray F, Engholm G, Ervik M, et al. (2022). NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 9.2 (23.06.2022). Association of the Nordic Cancer Registries. [cited 2023 Sep 8]. Available from: https://nordcan.iarc.fr/
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
